Announcements
On 6 June 2017, the World Health Organization (WHO) published updates to its ‘Essential Medicines List’ (EML). Read more here.

Extended deadline (from 1 July to 31 July) 2017 for call to submit papers on effectiveness and cost-effectiveness of screening and prevention of infectious diseases among newly arrived migrants in Europe. Read more here.

Eurosurveillance is on the updated list of the Directory of Open Access Journals and in the SHERPA/RoMEO database. Read more here.

Follow Eurosurveillance on Twitter: @Eurosurveillanc


In this issue


Home Eurosurveillance Weekly Release  2006: Volume 11/ Issue 26 Article 4
Back to Table of Contents
Previous
Next

Eurosurveillance, Volume 11, Issue 26, 29 June 2006
Articles

Citation style for this article: van Duijn C, Ruijs H, Timen A. Second probable case of vCJD in the Netherlands. Euro Surveill. 2006;11(26):pii=2991. Available online: http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=2991

Second probable case of vCJD in the Netherlands

C van Duijn1, H Ruijs2, ATimen2 (Aura.Timen@rivm.nl)

1National Surveillance of CJD, Erasmus MC, Rotterdam, The Netherlands
2Centre for Infectious Diseases, National Institute of Public Health and the Environment (RIVM), The Netherlands

A second probable case of variant Creutzfeldt-Jakob (vCJD) disease in a patient in the Netherlands was reported on 22 June 2006, by the National Institute of Public Health and the Environment (RIVM) [1].

The case was detected through national surveillance of CJD, which is coordinated at the Erasmus Medical Centre in Rotterdam. The probable diagnosis is based on magnetic resonance imaging and, clinical signs. The patient has no mutations associated with inherited CJD, and is homozygous for methionine at codon 129 of the prion protein gene. The diagnosis was reviewed by the United Kingdom’s National Creutzfeldt-Jakob Disease Surveillance Unit, which runs the European and Allied Countries Collaborative Study Group of CJD (EUROCJD, http://www.eurocjd.ed.ac.uk).
Patient data was collected by the national public health service together with the CJD surveillance unit, and revealed no specific exposure risks. The patient has never donated or received blood or tissue and has not undergone surgical procedures with risk of infection with prions. The patient has never lived in or travelled to the United Kingdom. Contaminated meat products remain the only plausible source of infection. Bovine spongiform encephalopathy (BSE) has been diagnosed in 82 cows in the Netherlands since 1997, according to data from the Ministry of Agriculture, Nature and Food Quality. [2]

This report brings the total number of vCJD cases reported to EUROCJD from outside the UK by June 2006 to 31: 17 in France, 4 in the republic of Ireland, 2 each in the United States and the Netherlands, and 1 in each of Italy, Canada, Saudi Arabia, Japan, Portugal and Spain. Six of these 31 cases were in people who lived in the UK for more than 6 months between 1980 and 1996 [3].

References:
  1. Rijksinstituut voor Volksgezondheid en Milieu (RIVM). Variant Creutzfeldt-Jakob vastgesteld bij tweede patiënt in Nederland. Press release, 22 June 2006. [in Dutch] (http://www.rivm.nl/persberichten/2006/Variant_CreutzfeldtJakob_vastgesteld.jsp)
  2. Ministerie van Landbouw, Natuur en Voedselkwaliteit. BSE-geval in Dinkelland. Press release, 3 March 2006. (www.minlnv.nl) [accessed 28 June 2006]
  3. The European and Allied Countries Collaborative Study Group of CJD (EUROCJD). Variant Creutzfeldt-Jakob Disease. Current Data (June 2006). (http://www.eurocjd.ed.ac.uk/vcjdworldeuro.htm) [accessed 28 June 2006]

back to top



Back to Table of Contents
Previous
Next

The publisher’s policy on data collection and use of cookies.

Disclaimer: The opinions expressed by authors contributing to Eurosurveillance do not necessarily reflect the opinions of the European Centre for Disease Prevention and Control (ECDC) or the editorial team or the institutions with which the authors are affiliated. Neither ECDC nor any person acting on behalf of ECDC is responsible for the use that might be made of the information in this journal. The information provided on the Eurosurveillance site is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician. Our website does not host any form of commercial advertisement. Except where otherwise stated, all manuscripts published after 1 January 2016 will be published under the Creative Commons Attribution (CC BY) licence. You are free to share and adapt the material, but you must give appropriate credit, provide a link to the licence, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.

Eurosurveillance [ISSN] - ©2007-2016. All rights reserved
 

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.